08:29 AM EDT, 10/07/2024 (MT Newswires) -- OPKO Health ( OPK ) subsidiary ModeX Therapeutics said Monday it has been awarded an additional $35 million in funding under a contract with the US Department of Health and Human Services' Biomedical Advanced Research and Development Authority to develop Covid-19 and flu vaccines.

The company said it will use the funding to develop a second novel antibody to Covid-19 from preclinical to phase 1 trials. It will also conduct preclinical research on gene-based antibodies to Covid-19.

Additionally, ModeX said it will begin development of influenza vaccines by activating a $16 million BARDA funding option.

Price: 1.5000, Change: +0.01, Percent Change: +0.67